{"entity":{"id":"cx-908","kind":"drug","name":"CX-908","aka":[],"tldr":"CX-908 is an experimental masked T-cell engager from CytomX Therapeutics, in preclinical development for solid tumours.","summary":"CX-908 is a masked T-cell engager (Probody TCB) from CytomX Therapeutics. A masked bispecific T-cell engager against P-cadherin and CD3; the source gives no further detail. Its furthest stage is preclinical development, for solid tumours. No clinical trial naming it is registered on ClinicalTrials.gov. It has not been shown to work in people.","status":"preclinical","asOf":"2026-11-03","links":[{"label":"CytomX Therapeutics: cytomx.com","url":"https://cytomx.com/pipeline/"}],"tags":["pipeline"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":["cd3"],"drugs":[],"companies":["cytomx-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"CX-908","modality":"Masked T-cell engager (Probody TCB)","mechanism":"A masked bispecific T-cell engager against P-cadherin and CD3; the source gives no further detail.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/cx-908/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"target":[{"id":"cd3","kind":"target","name":"CD3","route":"/targets/cd3/"}],"company":[{"id":"cytomx-therapeutics","kind":"company","name":"CytomX Therapeutics","route":"/companies/cytomx-therapeutics/"}]}}